 Subjects will be admitted to the research clinic at midday prior to dosing Day -1 and remain in-house until Day 8. Randomized subjects will receive a single dose of AEF0117 on Day 1. PK samples and safety assessments will be performed pre-dose and at different times post dose. Safety monitoring physical examinations, vital sign measurement, 12-lead electrocardiograms ECGs, clinical safety laboratory tests, and adverse event monitoring will be performed throughout the study. Psychometrics Bond Lader VAS, ARCI, POMS and C-SSRS tests will be performed. 